Zoetis Inc. (ZTS) Fair Value 2026

ZTS · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.3 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (6/100)

Quick Summary — As of 2026-08-27, Zoetis Inc. (ZTS) trades at $75.02, versus a $101.58 median fair value across its 11 active models — 35.4% above the current price. QOC: 9.3/10. Value Trap Risk: 6/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $131.94.

Key Facts

Ticker
ZTS
Price
$75.02
Quality Score
9.3/10
Value Trap Risk
6/100
Models Active
11/13
Last Updated
Strength: Bayesian DCF suggests +75.9% upside with 75% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Zoetis Inc. (ZTS) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Zoetis Inc. (ZTS) appears undervalued as of : the median of 11 independent fair value estimates is $101.58, 35.4% above the current price of $75.02. Estimates range from $44.65 to $273.48. ZTS scores 9.3/10 on fundamental quality and 6/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ZTS’s +35.4% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Zoetis Inc. Stock in 2026? →

What Fair Value Does Each Model Give ZTS?

11 Intrinsic Value Models vs. Current Price ($75.02)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $131.94 +75.9%
Intrinsic · High Conviction
 $66.60 -11.2%
Ensemble · Medium Conviction
 $101.58 +35.4%
Intrinsic · High Conviction
 $44.65 -40.5%
Unlock the Full Matrix

Access 7 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is ZTS's Fair Value Range?

Spread across 11 independent models · $44.65 to $273.48

CirclFi's 11 active models place Zoetis Inc. (ZTS) between $44.65 and $273.48 per share, a spread of 225% of the median. The median of that range — $101.58 — is the fair value CirclFi publishes for ZTS, against a current price of $75.02.

Low · EROICHigh · Markov DDM
$44.65median $101.58$273.48
Where the range comes from
Most bearish modelEROIC Spread$44.65
Most bullish modelMarkov DDM$273.48
Model agreement6 bullish · 3 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for ZTS. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on ZTS, not a CirclFi price target. How each model works →

What Is Zoetis Inc. (ZTS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Zoetis Inc. presents a highly debated valuation profile at its current price of $75.02. The median intrinsic value is estimated at $101.58 (+35.4% median upside), masking a wide model spread between the 6 bullish models and 3 bearish models. Model dispersion is worth noting: Markov DDM targets $273.48 (+264.5%), versus EROIC at $44.65 (-40.5%). This +305.0% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, Bayesian DCF, EPV, EROIC lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About ZTS?

11 of 13 models are currently active for ZTS. Of these, 7 models suggest upside while 4 models suggest overvaluation. Taken together, their median fair value for ZTS is $101.58 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $131.94 on its own, implying +75.9% upside from the current price. See which stocks rank higher →

How Does ZTS Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, ZTS ranks #3 by Quality of Company score. CirclFi's QOC score of 9.3/10 evaluates 32 fundamental signals. A score of 9.3 places ZTS in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

As a biopharma enterprise, Zoetis Inc. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating ZTS should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ZTS a Value Trap?

CirclFi's Value Trap algorithm assigns ZTS a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Zoetis Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Zoetis Inc. is rated at 9.3/10. This elite-tier score ranks among the highest-quality businesses in our coverage universe.

The gap between the most bullish and bearish model spans +305.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ZTS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ZTS's 11 active models, average confidence is 55%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Zoetis Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

9 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4LNTHLantheus Holdings, Inc.QOC 9.3UTHRUnited Therapeutics CorporationQOC 9.6NBIXNeurocrine Biosciences, Inc.QOC 9.1AKANAkanda Corp.QOC 1.3ANIPANI Pharmaceuticals, Inc.QOC 9.0EBSEmergent BioSolutions Inc.QOC 7.1CABRCaring Brands, Inc.QOC 6.0PLNHPlanet 13 Holdings Inc.QOC 4.7

Read investment analysis: AMPH · LNTH · UTHR · NBIX · AKAN · ANIP · EBS · CABR · PLNH

Which Other Stocks Have a Similar Quality Score to ZTS?

7 companies across all industries closest to ZTS’s Quality of Company score of 9.3/10.

WSMWilliams-Sonoma, Inc.QOC 9.3ALRMAlarm.com Holdings, Inc.QOC 9.3CBOECboe Global Markets, Inc.QOC 9.3FSLRFirst Solar, Inc.QOC 9.3FSMFortuna Mining Corp.QOC 9.3ALLEAllegion plcQOC 9.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: WSM · ALRM · CBOE · FSLR · FSM · ALLE · NVDA

Where Does ZTS Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

ZTS is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Zoetis Inc.’s Valuation?

What is Zoetis Inc.'s intrinsic value in 2026?

CirclFi puts Zoetis Inc. (ZTS)'s intrinsic value at $101.58 — the median of 11 independent model estimates as of 2026-08-27, ranging from $44.65 to $273.48. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $131.94 on its own. The Quality of Company score is 9.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ZTS overvalued or undervalued right now?

At $75.02, 7 of 11 active models suggest ZTS may be undervalued, while 4 indicate potential overvaluation. The median of all 11 fair value estimates is $101.58, 35.4% above the current price of $75.02 — a consensus view that ZTS is undervalued. The assessment depends on which methodology best fits Zoetis Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 9.3 mean for ZTS?

Zoetis Inc.'s QOC of 9.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ZTS?

CirclFi analyzes ZTS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on ZTS?

Of the 11 models currently active on ZTS, Markov DDM is the most bullish at $273.48 per share, and EROIC Spread is the most bearish at $44.65. CirclFi's published fair value for ZTS is the median of that range, $101.58, not either extreme. The gap between the two ends equals 225% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is ZTS a value trap in 2026?

Zoetis Inc.'s Value Trap score is 6/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Zoetis Inc. (ZTS) has a median fair value of $101.58 — 35.4% above the current price of $75.02 — as of 2026-08-27.” Source: circlfi.com/stock/ZTS/ · Methodology
Primary sources for this ZTS valuation
  • Financial statements: Zoetis Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001555280) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ZTS as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on ZTS.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for ZTS Unlock All 11 — $39/mo